The JPM26 trading podcast falls short of expectations. Despite the lackluster closing of deals, trends were identified from company presentations. These include the upcoming patent cliff in pharmaceuticals. Another trend is the growth of artificial intelligence in the field of medicine. JP Morgan's net profit fell 7% to $13 billion. Adjusted earnings per share came in at $5.23, beating expectations of $4.85. The bank expects net interest income of $95 billion in 2026. Investment banking fees fell 5% to $2.35 billion.[1][3]